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Abstract
Introduction Activator protein-2 (AP-2) α and AP-2γ
transcription factors contribute to ERBB2 gene overexpression
in breast cancer. In order to understand the mechanism by
which the ERBB2 gene is overexpressed we searched for novel
AP-2 interacting factors that contribute to its activity.
Methods Ku proteins were identified as AP-2α interacting
proteins by glutathione serine transferase (GST)-pull down
followed by mass spectrometry. Transfection of the cells with
siRNA, expression vectors and reporter vectors as well as
chromatin immunoprecipitation (ChIP) assay were used to
ascertain the implication of Ku proteins on ERBB2 expression.
Results Nuclear proteins from BT-474 cells overexpressing AP-
2α and AP-2γ were incubated with GST-AP2 or GST coated
beads. Among the proteins retained specifically on GST-AP2
coated beads Ku70 and Ku80 proteins were identified by mass
spectrometry. The contribution of Ku proteins to ERBB2 gene
expression in BT-474 and SKBR3 cell lines was investigated by
downregulating Ku proteins through the use of specific siRNAs.
Depletion of Ku proteins led to downregulation of ERBB2
mRNA and protein levels. Furthermore, reduction of Ku80 in
HCT116 cell line decreased the AP-2α activity on a reporter
vector containing an AP-2 binding site linked to the ERBB2 core
promoter, and transfection of Ku80 increased the activity of AP-
2α on this promoter. Ku siRNAs also inhibited the activity of this
reporter vector in BT-474 and SKBR3 cell lines and the activity
of the ERBB2 promoter was further reduced by combining Ku
siRNAs with AP-2α and AP-2γ siRNAs. ChIP experiments with
chromatin extracted from wild type or AP-2α and AP-2γ or Ku70
siRNA transfected BT-474 cells demonstrated Ku70
recruitment to the ERBB2 proximal promoter in association with
AP-2α and AP-2γ. Moreover, Ku70 siRNA like AP-2 siRNAs,
greatly reduced PolII recruitment to the ERBB2  proximal
promoter.
Conclusions Ku proteins in interaction with AP-2 (α and γ)
contribute to increased ERBB2 mRNA and protein levels in
breast cancer cells.
Introduction
Breast cancer is the most common cancer in women in Europe
[1]. Accumulation of different molecular alterations character-
izes this complex disease. Five major breast cancer sub-
groups have been distinguished according to gene expression
signatures [2,3]. One of these subgroups is characterized by
ERBB2/Her2  gene amplification and overexpression. This
alteration is present in about 20% of breast cancers and was
found to be predictive of poor prognosis before the develop-
ment of ERBB2 targeted drugs [4-6].
The ERBB2 gene encodes for p185-erbB2, which is a trans-
membrane protein with intrinsic tyrosine kinase activity belong-
ing to the EGF receptor (EGFR) family. No growth factor
AP-2: Activator Protein 2; AP2BS: AP-2 binding site; bp: base pairs; ChIP: chromatin immunoprecipitation; EGFR: EGF Receptor; GCK: Glucoki-
nase; GSH: Glutathion; GST: Glutathione Serine Transferase; Luc: Luciferase; MS: Mass Spectrometry; PAGE: Poly-Acrylamide Gel Electrophore-
sis; PBS: Phosphate Buffer Saline; Pol II: Polymerase II; RT: Room Temperature; siRNA: small interfering RNA.Breast Cancer Research    Vol 11 No 6    Nolens et al.
Page 2 of 11
(page number not for citation purposes)
recognizing specifically ERBB2  with high affinity has been
identified. Consequently, p185-erbB2 is assumed to be acti-
vated by hetero-dimerization with another ligand-activated
member of the EGFR family [6].
The high levels of p185-erbB2 measured in breast cancer cells
result from gene amplification and increased transcription
rates [7,8]. In order to investigate the biology of these specific
breast cancers, we chose to study the deregulation of ERBB2
gene expression. Analyses of the ERBB2 promoter have led to
the identification of several regulatory sequences through
which the gene is overexpressed. AP-2, Ets and YB-1 tran-
scription factor families bind to some of these regulatory
regions and have been shown to play a role in ERBB2 overex-
pression. Ets family transcription factors contribute to ERBB2
overexpression by binding to the proximal promoter [9]. YB-1
factors act through binding sites located 815 to 1129 bp
upstream the main transcription initiation site [10], whereas
AP-2 binding sequences (AP2BS) have been identified in the
proximal [11-13] and distal [14] regions of the promoter.
The AP-2 transcription factor family contains five members:
AP-2α, β, γ, δ and ε. All have a similar 50 kDa apparent molec-
ular mass and are able to form homo- and hetero-dimers. They
bind specific DNA sequences, AP2BS, through their con-
served helix-span-helix DNA binding domain.
The involvement of AP-2α and AP-2γ factors in ERBB2 over-
expression has been described in several breast cancer cell
lines [11-13,15]. Besides the ERBB2 gene, AP-2 factors con-
trol the expression of several target genes implicated in the
control of cell growth, differentiation and carcinogenesis [16].
AP-2 factors control transcription in association with transcrip-
tional cofactors [17]. Among them, PC4, PARP [18], CITED-
2, CITED-4 and CBP/p300 [19], as well as YY1 [20], have
been shown to interact with and to contribute to AP-2 tran-
scriptional activity. In our own research, we have observed a
good correlation between p185-erbB2, AP-2α and YY1 expres-
sion levels in primary breast tumor samples [21]. Besides their
role in transcription, cofactors are also important for the pro-
tection of AP-2 against proteasomal degradation [22].
In order to improve the current understanding of AP-2 (α and
γ) activity, we sought here to identify further AP-2α interacting
factors contributing to ERBB2 gene overexpression in breast
cancer cells. We used a proteomic approach to isolate pro-
teins interacting with this transcription factor in a BT-474
breast cancer cell line. Ku70 and Ku80 were identified by
mass spectrometry among the AP-2α interacting proteins.
Ku 70 and Ku80 hetero-dimers are mostly known for their role,
in association with DNA-PK, in the repair of DNA double
strand breaks. However, it has been shown that Ku70 and
Ku80 are involved in transcription regulation either by binding
directly to DNA or through interaction with transcription fac-
tors [23]. Ku factors might also play a role in cancer [24].
We show that siRNAs targeting Ku mRNAs downregulate
ERBB2 mRNA and protein levels. The use of reporter vectors
containing the ERBB2 proximal promoter demonstrated that
Ku70 and Ku80 proteins are involved in ERBB2 transcription
regulation. Moreover, we show by ChIP assays that Ku70 pro-
tein is recruited to the ERBB2 gene promoter and its absence
decreases AP-2α and AP-2γ recruitment. Furthermore, Ku70
recruitment is dependent on the expression of AP-2α and AP-
2γ. These results contribute to a better understanding of the
mechanism by which AP-2 factors upregulate ERBB2 gene
expression in breast cancer cells.
Materials and methods
Cell lines
All the human cell lines (BT-474, ZR-75.1, MDA-MB-231,
MCF-7 and SK-BR3, HepG2) were purchased from the Amer-
ican Tissue Culture Collection (Manassas, VA, USA). HCT116
and the derived 70/32 (Ku80+/-) cell lines were gifts from Dr.
EA Hendrickson [25]. All the cells were cultured in the recom-
mended media supplemented with 10% (v/v) fetal bovine
serum, 2 mM glutamine and 100 μg/ml penicillin/streptomycin
(Lonza, Basle, Switzerland).
Antibodies
Mouse anti-AP-2α (3B5) [20], rabbit anti-AP-2α (C-18) [20],
mouse AP-2γ (6E4/4) [21], goat anti-Ku70 (C-19) [26], goat
anti-Ku80 (C-20) [26], mouse anti-Ku80 (B-1) [27], and con-
trol mouse, goat and rabbit IgG antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA. Anti
RNA Polymerase II (clone CTD4H8) and anti-β-actin (mAb-
cam 8226) antibodies were obtained from Abcam (Cam-
bridge, UK).
Plasmids and constructs
The pGEX2T-GST-AP2 and -GST vectors were gifts from Dr.
Kannan [28]. The p86-AP2BS-Luc and p86-AP2BS mut-Luc
plasmid reporter vectors (pGL3 basic reporter vector,
Promega, Madison, WI, USA) have been previously described
by Vernimmen et al [13]. The SV40-Luc control vector (pGL3
control vector) was purchased from Promega. The AP-2α and
the corresponding control expression vectors [29] have been
described previously [20]. Ku80 expression vector was a gift
from Dr. Chen [30].
GST-pull-down
GST-fusion proteins were expressed and purified according to
the procedures provided by Amersham Bioscience (Bucking-
hamshire, UK). Their purification and the pull-down assay were
carried out by using the MagneGST™ Pull-Down System
(Promega, Madison, WI, USA). The manipulation (incubation
and washing) of the beads was automated by the KingFisher
robot (Thermo Fisher Scientific, Waltham, MA, USA). Wash-Available online http://breast-cancer-research.com/content/11/6/R83
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ing buffer was phosphate buffer saline (PBS)/0,01% Tween.
Procedure: 15 μl of MagneGST beads were washed twice
with the washing buffer. Beads were incubated with 50 μl of
sonicated E. coli (Bl21) transformed with plasmids encoding
GST or GST-AP2alpha fusion protein in 250 μl of PBS for 30
min at room temperature (RT). After washing twice with 400 μl
of washing buffer, beads bound with GST or GST-AP2 were
incubated for 50 minutes with 100 μg (35 μl) of nuclear pro-
teins extracted from BT474 at RT in 180 μl of PBS. After
washing the beads three times with 400 μl, the interacting pro-
teins were finally eluted by 8 M urea for 2D gel electrophore-
sis, or with Laemmli Buffer (2% SDS, 10% glycerol, 5% 2-
mercaptoethanol, 0.125 M Tris HCl pH 6.8) for western blot-
ting.
DNase I treatment - GST-AP2 beads incubated with the
nuclear protein extracts were washed twice with PBS and sus-
pended in DNase I buffer (40 mM Tris HCl, 10 mM NaCl, 6
mM MgCl2, 1mMCaCl2, pH 7.9). The suspension was incu-
bated with increasing concentrations of DNase I (Roche,
Basel, Switzerland) for one hour at 37°C. The suspension was
washed three times with PBS, resuspended in Laemmli buffer
and the bound proteins were eluted by vortexing during 10
min. Ku70, Ku80 and AP-2 were revealed by western blotting.
DNA quantity was estimated by the picoGreen assay (Invitro-
gen, Carlsbad, CA, USA).
Two-dimensional gel electrophoresis and mass 
spectrometry
These techniques were performed as described previously
[31], except that the proteins were directly loaded onto IPG
strips (non linear IPG strip pH 4-10; Amersham, GE Europe
(Buckinghamshire, UK). Liquid chromatography was carried
out in an UltiMate™ pump/detection module, FAMOS™ micro
autosampler, Switchos™ micro switching module (LC Pack-
ings, Dionex, Sunnyvale, CA, USA). The mass analysis was
carried out in an ion trap Esquire HCT (Bruker Daltonics,
Bremen, Germany) mass spectrometer. The database search
was performed using a Mascot local server (Matrix Science,
London, UK).
Immunoblotting
Proteins were separated on an SDS-PAGE (10%) and trans-
ferred to a PVDF membrane (Millipore, Billerica, MA, USA).
Primary antibodies were used at a 1:1000 dilution. Secondary
antibodies coupled with peroxydase (DAKO, Glostrup, Den-
mark) at a 1:4000 dilution were detected using the ECL sys-
tem (Thermo Fisher Scientific).
Immunoprecipitation was carried out using Dynabeads Pro-
tein G (Invitrogen), according to the manufacturer's recom-
mended protocol, using acetate sodium buffer for antibodies
binding. Anti-AP-2α (C-18), Ku70 (C-19), Ku86 (C-20) anti-
bodies and control antibody were used.
Transient transfection assays of reporter vectors
HCT116, 70/32 (HCT116 Ku80 +/-), BT-474 and SKBR3
cells were transfected using FuGENE HD reagent (Roche
Applied Science). The cells (3 × 105) were plated onto 24 mm
tissue culture dishes, treated with FuGENE HD/DNA (ratio of
3:1) and incubated for 40 h in complete medium. Cells were
then harvested. Lysis and enzymatic activity measures were
carried out using the Luciferase Reporter Gene Assay kit
(Roche Applied Science). Enzymatic activity was measured in
a Wallac Victor™ luminometer (PerkinElmer, Waltham, MA,
USA). The data were normalized to total protein content.
Transient siRNA transfection
siRNAs were transfected at a 30 nM final concentration using
the Calcium Phosphate precipitation technique [32]. Cells
were transfected twice at 48 h intervals. As a control, cells
were transfected with the negative control siRNA OR-0030-
neg05 (Eurogentec, Seraing, Belgium). The AP-2 siRNAs
used were as previously described [14]. Other siRNAs were:
Ku70-1, 5-GUGUGUACAUCAGUAAGAU; Ku70-2, 5-CAG-
GCAUCUUCCUUGACUU; Ku80-1, 5-GAAGAGGCAUAU-
UGAAAUA; Ku80-2, 5-CUCCAUUCCUGGUAUAGAA.
Reverse Transcription-Polymerase Chain Reaction (RT-
PCR)
Total RNA was extracted after 90 hours of siRNA transfection
treatment, using the High Pure RNA Isolation kit (Roche
Applied Sciences). RNA quantification was carried out on a
Nano Drop 1000 (Thermo Fisher Scientific). Reverse tran-
scription was performed on 1 μg of total extracted RNA. Real
time PCR analysis was performed on an ABI Prism 5700
apparatus (Applied Biosystems, Foster City, CA, USA) using
the standard protocol. All the results were reported to the β-2-
microglobulin mRNA quantity. The primers used were as pre-
viously described [21], except for Ku70: 5-AGAAGCAAAC-
CGCCTGTA and 5-CAAGCCTCCTCCAATAAAGC; and
Ku80: 5-TGCAGCAAGAGATGATGAGG and 5-GAAAG-
GCAGCTGCACATACA.
Chromatin Immunoprecipitation (ChIP)
Chromatin Immunoprecipitation was carried out using Dyna-
beads Protein G (Invitrogen). The previously described proto-
col [33] was adapted for higher chromatin quantities. On
average for each immunoprecipitation reaction, 30 μg of chro-
matin DNA was precipitated with 4 μg of antibody. Rabbit anti-
AP-2α (C-18), goat anti-Ku70 (C-19) and mouse anti-Ku80
(C-20) were used. Immunoprecipitation with pre-immune sera
from the same animal species (Ig) or mock immunoprecipita-
tion (NoAb) served as negative controls. Recovered DNA was
quantified by real time PCR or by end-point PCR followed by
agarose gel electrophoresis and the results were compared to
known quantities of chromatin. The gene-specific primer
sequences were: -6900 primers: 5-GCAGTAGCAAGCATC-
GAGTT and 5-TGGATCATCACAAAGGTTTTCA (-6981 bp
to -6780 bp); -500-bp ERBB2 primers, 5-GACTGTCTCCTC-Breast Cancer Research    Vol 11 No 6    Nolens et al.
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CCAAATTT and 5-CTTAAACTTTCCTGGGGAGC (fragment
-575 to -349 bp); -100-bp ERBB2 primers, 5-GCGAAGA-
GAGGGAGAAAGTG and 5-GGGGAATCTCAGCT-
TCACAA; GCK primers, 5-GGTAGAGCAGATCCTGGCAG
AG and 5-TGAGCCTTCTGGGGTGGAGCGCA. Dilutions of
known quantities of input DNA were used to quantify the PCR
products.
Results
Identification of novel AP-2α interacting proteins
Our goal was to identify novel proteins interacting with AP-2,
which contribute to the factor's transcriptional activity. Nuclear
protein extracts from BT-474 breast cancer cells were incu-
bated with a Glutathione-Serine-Transferase/AP-2α (GST-
AP2) hybrid protein, linked to glutathione (GSH) coated mag-
netic beads. Beads coated with expressed GST alone were
used as a negative control. After washes, the proteins bound
to GST-AP2 or GST coated beads were eluted and resolved
on two-dimensional gel electrophoresis. Two proteins migrat-
ing with an apparent molecular mass comprised between 70
and 100 kDa were repeatedly detected among the proteins
eluted exclusively from the GST-AP2 coated beads (Figure
1A). The corresponding spots were cut out of the gel, the pro-
teins digested, and the resulting peptides analyzed by LC-MS/
MS. The proteins were identified as Ku70 and Ku80 [see
Additional data file 1]. Most of the other spots on the 2D-gel
recovered from the GST-AP2 pull down, were identified as
GST or AP-2α fragments.
The presence of Ku proteins among the proteins eluted from
the GST-AP2 beads was confirmed by immunoblotting with
Ku specific antibodies (Figure 1B). Moreover, the interaction
between AP-2 and Ku proteins was controlled by co-immuno-
precipitation, using AP-2, Ku70 and Ku80 specific antibodies
(Figure 1C). To verify that the binding of Ku proteins to AP2 is
not due to the DNA contaminating the protein extracts [34],
the mixture of GST-AP2 beads and nuclear proteins were
incubated with increasing concentrations of DNase I. The
Figure 1
Identification of the Ku proteins interacting with AP-2α Identification of the Ku proteins interacting with AP-2α. (a) Two-dimensional gel electrophoresis of nuclear proteins eluted from GST AP-2α coated 
beads or beads coated with GST alone (GST). The gels were silver stained and the proteins retained on GST AP-2α beads were identified by mass 
spectrometry. Arrows show the location of Ku80 (up) and Ku70 (down). Molecular masses are indicated on the left and the pH scale on the top of 
the gels. (b) The presence of AP-2α and Ku proteins in the eluted fractions was verified by immunoblotting (IB) and compared to a fraction of the 
input (IN). (c) Co-immunoprecipitation (IP) of AP-2 and Ku proteins by AP-2, Ku70 and Ku80 antibodies or an Ig control (Ig Ctl). The proteins were 
revealed by immunoblotting (IB).Available online http://breast-cancer-research.com/content/11/6/R83
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result, [see Additional data file 2] showed a decrease in bound
Ku proteins after treatment with low DNase I concentrations.
However, the quantity of recovered Ku proteins remained con-
stant when the enzyme concentration was raised, despite the
steady decrease in contaminating DNA. This result indicates
that the association of Ku to AP-2 is specific.
Ku70/80 depletion induces downregulation of ERBB2 
expression
Figure 2 presents Ku70, Ku80 AP-2α, AP-2γ, and p185-erbB2
protein levels in the cytoplasmic and the nuclear fractions of
breast cancer (BT-474, SKBR3, ZR-75.1, MCF-7, MDA-MB-
231), colon cancer (HCT-116) and hepatoma (HepG2) cell
lines. In most cells, Ku70 and Ku80 proteins were detected in
both the nuclear and the cytoplasmic fraction, with the excep-
tion of MCF-7 and HepG2 cell lines where Ku80 was exclu-
sively nuclear. In comparison, AP-2α and AP-2γ factors were
detected only in the nuclear fraction of BT-474, SKBR3 and
ZR-75.1 breast cancer cells that overexpress p185-erbB2 pro-
tein.
Next, we studied the consequence of Ku70 and Ku80 down-
regulation on the ERBB2 expression level. For that purpose,
Ku70 and Ku80 were inhibited by the transfection of specific
siRNAs in two ERBB2 overexpressing cell lines, BT-474 and
SKBR3. In parallel, the cells were transfected with a combina-
tion of AP-2α and AP-2γ (AP-2αγ) siRNAs, previously shown
to downregulate ERBB2 expression [21]. The levels of Ku70,
Ku80, AP-2α, AP-2γ and p185erbB2 proteins in BT-474 were
assessed by western-immunobloting 96 hours after transfec-
tion (Figure 3A). Each siRNA inhibited its own target protein.
Moreover, Ku70 and Ku80 siRNAs reduced both Ku70 and
Ku80 protein levels, in agreement with published data [35,36].
The results of similar experiments on SKBR3 cells are pre-
sented in Additional data file 3, Figure A. Ku70 and Ku80 siR-
NAs reduced p185-erbB2 levels less efficiently in SKBR3 than
in BT-474 cells. We have to stress that AP-2αγ siRNAs were
also less efficient in SKBR3 than in BT-474 cells.
In order to gain a more precise view of the cooperation
between Ku and AP-2 proteins on ERBB2 gene transcription,
the ERBB2 mRNA level was precisely quantified by real-time
RT-PCR in Ku and AP-2αγ siRNA transfected cells. The
ERBB2 transcript levels in cells transfected with the siRNAs
were compared to the mRNA levels in cells transfected with
the Negative (Neg) siRNA [Figure 3B and Figure B in Addi-
tional data file 3]. ERBB2 transcript levels were similarly
reduced by Ku70 and Ku80 siRNAs in BT474 cells. The AP-
2αγ siRNAs were more effective, reducing the ERBB2 tran-
script level by about 50%. Co-transfection of Ku and AP-2αγ
siRNAs did not reduce further the ERBB2 mRNA level in these
cells. While the Ku70 siRNA was as effective in SKBR3 as in
BT-474 cells, Ku80 and AP-2 αγ s iR NAs were m uch less
effective. In contrast with BT-474 cells, in SKBR3 cells a com-
bined effect of Ku70 and AP-2 siRNAs was observed.
Ku70/80 regulate ERBB2 promoter transcriptional 
activity
To investigate the transcriptional control of ERBB2  gene
expression by Ku and AP-2 proteins, we compared the
HCT116 cell line and its derived 70/32 cell line, knocked out
for one Ku80 allele [25]. Ku80 protein level in 70/32 cells was
decreased by about 40-60% in comparison with the wild-type
HCT116 cells (Figure 4C). The role of the interaction between
Ku and AP-2 on ERBB2 gene expression was studied by
transfecting in both cell lines a luciferase- reporter vector con-
taining a wild type or a mutant AP-2 binding site (AP2BS) (Fig-
ure 4A). The cells were cotransfected with AP-2α and/or
Ku80 expression vectors or the corresponding empty vectors.
The luciferase activity in the cells transfected with the empty
expression vector was considered as equal to one. As previ-
ously shown [13,20], AP-2α stimulated the activity of the
reporter containing the wild type AP2BS (Figure 4B). How-
ever, the activation was reduced in 70/32 cells expressing
less Ku80. Ku80 expression vector alone had no effect on the
promoter activity. However, co-transfection of Ku80 with AP-
2α expression vectors induced a significant increase in the
promoter activity in both cell lines. Interestingly, transfection of
Ku80 restored the activation capacity of AP-2α in 70/32 cell
Figure 2
Ku70 and Ku80 protein levels in cytoplasm and nuclei of cancerous cell lines Ku70 and Ku80 protein levels in cytoplasm and nuclei of cancerous cell lines. 60 μg of nuclear and cytoplasmic proteins extracted from the cell lines 
were resolved by 10% PAGE. The Ku80, Ku70, AP-2α, AP-2γ and p185erbB2 proteins were revealed by immunoblotting. The antibodies are indi-
cated on left. Beta-actin (β-actin) protein was used as a loading control.Breast Cancer Research    Vol 11 No 6    Nolens et al.
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line. Figure 4C presents the AP-2α and Ku80 protein levels in
the transfected cells.
To complete this investigation, the reporter vectors activities
were measured in BT-474 (Figure 5) and SKBR3 [see Addi-
tional data file 4] cells 72 hours after transfection of Ku and
AP-2 siRNAs (Figure 5). The Luciferase activity in cells trans-
fected with the negative siRNA was considered as equal to
one in each condition. As expected, downregulation of AP-2α
and AP-2γ inhibited only the activity of the reporter containing
the functional AP2BS (p86-AP2BS-Luc). Ku70 or Ku80 siR-
NAs also inhibited significantly the activity of this reporter vec-
tor. Furthermore, when Ku70 or Ku80 siRNAs were co-
transfected with the AP-2αγ siRNAs, the activity of p86-
AP2BS-Luc was further reduced. In contrast, AP-2αγ, Ku70
Figure 3
Effect of Ku70/Ku80 and AP-2 downregulation on ERBB2 protein lev- els in BT-474 cells Effect of Ku70/Ku80 and AP-2 downregulation on ERBB2 protein lev-
els in BT-474 cells. (a) Immunoblot showing p185-erbB2, Ku70, Ku80, 
AP-2α, AP-2γ and beta-actin (β-actin) protein levels in cells transfected 
with the siRNAs indicated above the photograph. (b) Percent reduction 
of ERBB2 mRNA levels compared to the Neg siRNA condition in cells 
transfected with the different siRNAs indicated below the figure. 
ERBB2 mRNA levels were quantified in triplicate by Real-time RT-PCR, 
and corrected for beta-2-microglobulin mRNA levels.
Figure 4
Influence of Ku80 on AP-2α transcriptional activity on ERBB2 gene  promoter Influence of Ku80 on AP-2α transcriptional activity on ERBB2 gene 
promoter. (a) Schematic representation of the reporter vectors used in 
this study. All the reporter vectors contain 86 bp of the ERBB2 core 
promoter. The black diamond indicates the CAAT box; the black trian-
gle the TATA box. The sequence of the AP2BS is that of AP-2 binding 
sites located at -512 bp from the main ERBB2 transcription start site. 
Mutation of three nucleotides abrogates the binding of the transcription 
factor to AP2BSmut [25]. (b) Variation of luciferase activity in cells 
transfected with (+) AP-α expression vector alone or with the Ku80 
expression vector, in HCT116 and in 70/32 (HCT116 Ku80+/-) cell 
lines; compared with the activity in the cells transfected with the corre-
sponding empty expression vectors (-). (c) Western blot showing the 
levels of AP-2α and Ku80 proteins in the cells transfected with the cor-
responding expression vectors.Available online http://breast-cancer-research.com/content/11/6/R83
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and Ku80 siRNAs did not modify significantly the activity of the
vector containing the mutated AP2BS (p86-AP2BS mut-Luc).
However, co-transfection of AP-2αγ with Ku70 or Ku80 signif-
icantly reduced the activity of the reporter containing the
mutant AP2BS.
Together, these results suggest that Ku proteins regulate
ERBB2 gene expression through the proximal promoter, by an
AP-2 dependent mechanism.
Ku70/80 proteins are recruited to the ERBB2 proximal 
promoter
Next, we investigated Ku binding to ERBB2 gene promoter by
chromatin immunoprecipitation (ChIP). Cross-linked chroma-
tin was extracted from BT-474 (Figure 6A) and SKBR3 cells
[Supplemental Data, Figure S.4]. We also extracted chromatin
from the same cell type transfected with Ku or AP-2αγ siRNAs.
Chromatin fragments were immunoprecipitated with antibod-
ies recognizing AP-2α and AP-2γ (AP-2), Ku70, Ku80 and
RNA Polymerase II (Pol II). The Pol II antibody was used as a
positive control for the recruitment of the transcriptional
machinery on the ERBB2 promoter [14,20,37]. Three regions
of the ERBB2 promoter were amplified (Figure 6B). The -500
bp region contains a high affinity AP2BS [12]. The -100 bp
region contains the CAAT and TATA boxes and corresponds
to the ERBB2 core promoter. The -6900 bp sequence was
used as an AP2BS negative control [14]. The Ku binding
sequence from the Glucokinase (GCK) gene promoter was
used as a positive control for Ku proteins binding [37]. Exper-
iments were repeated three times and the average quantities
of DNA were reported to the "No antibody" (NoAb) condition
(Figure 6C).
In untreated BT-474 cells, Ku70 antibody immunoprecipitated
most efficiently the -500 bp DNA sequence of the ERBB2
gene promoter (Figure 6C, black columns). In agreement with
previously published data, AP-2 antibody also immunoprecipi-
tated the same region [14,20]. Interestingly, AP-2 antibodies
also immunoprecipitated the GCK sequence. The -500 bp, -
100 bp and GCK sequences were efficiently recovered from
Pol II specific immunoprecipitations. No DNA was recovered
in the ChIP experiments using the C-20 Ku80 specific anti-
body (data not shown). Although the C-20 antibody has been
successfully used in our immunoprecipitation experiments
(Figure 1C) and published in ChIP data [26], we did not suc-
ceed to immunoprecipitate even the GCK control sequence
with this antibody. As the -6900 bp region is devoid of an
AP2BS, we consider this signal as background. Compared to
BT-474 cells, immunoprecipitation with Ku70 and PolII anti-
bodies of the ERBB2 and GCK promoter regions in SKBR3
was very poor [see Additional data file 5].
AP-2αγ siRNAs reduced significantly the amount of DNA cor-
responding to the 500 bp region recovered after immunopre-
cipitation with the AP-2 antibody. Interestingly, AP-2αγ
siRNAs drastically reduced all DNA fragments recovered after
ChIP using the Ku70 antibody in the BT-474 cell line. The
recruitment of the DNA fragment from the GCK promoter after
the Ku70 ChIP was also reduced. These siRNAs completely
inhibited Pol II recruitment to the ERBB2 and GCK promoters.
In the two cell lines, Ku70 siRNA reduced AP-2 recruitment to
Figure 5
Ku70/80 proteins control ERBB2 promoter activity in BT-474 cell line Ku70/80 proteins control ERBB2 promoter activity in BT-474 cell line.  Relative luciferase activity in cells transfected with the reporter vectors indi-
cated above the figure, 72 hours after transfection of the siRNAs shown under each bar. The fold induction is the ratio between the luciferase activ-
ities in the cells transfected with the siRNA of interest and the activity measured in cells transfected with siRNA Neg. Luciferase activity was 
normalized to total protein content.Breast Cancer Research    Vol 11 No 6    Nolens et al.
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the ERBB2 and GCK gene promoters. This siRNA also com-
pletely inhibited the recruitment of Ku70 and PolII to the pro-
moters we had investigated in the BT-474 cell line.
The ChIP results suggest that both Ku and AP-2 proteins are
recruited on the ERBB2 proximal promoter in BT-474 cells.
Moreover, the binding of both factors is necessary for the
recruitment of transcription machinery on the ERBB2 gene
promoter in BT-474 and SKBR3 cell lines.
Discussion
The aim of this study was to identify novel proteins interacting
with and contributing to AP-2 transcription factor activity.
Using GST-pull-down coupled with two-dimensional gel elec-
trophoresis and mass spectrometry, Ku70 and Ku80 proteins
were identified as AP-2α interactors. AP-2/Ku interaction was
confirmed by co-immunoprecipitation. We showed that down-
regulation of Ku proteins by siRNAs induced a strong reduc-
tion in ERBB2 mRNA and protein levels in BT-474 and
SKBR3 cells. These siRNAs also inhibited the activity of
reporter vectors containing the ERBB2  proximal promoter.
ChIP experiments revealed that Ku70 proteins were recruited
Figure 6
Ku70 is recruited to the ERBB2 promoter and is necessary for the recruitment of AP-2 and of RNA PolymeraseII Ku70 is recruited to the ERBB2 promoter and is necessary for the recruitment of AP-2 and of RNA PolymeraseII.  (a) Chromatin extracted from BT-
474 cells transfected or not with AP-2 (αγ) or Ku70 siRNAs (above) was shared by sonication to fragments of 100-500 bp. Protein expression was 
verified by immunoblot. (b) Schematic representation of the ERBB2 promoter illustrating the amplified regions. (c) DNA amplified after chromatin 
immunoprecipitation with AP-2, Ku70 and RNA Polymerase II (Pol II) specific antibodies. ChIP with control antibodies (Ig) are presented on the left 
of each experimental point (R: rabbit, G: goat and M: mouse). Graphs show the fold enrichment of the target sequence, compared to the no-anti-
body (NoAb) condition. The error bars were calculated from the results of three independent ChIP experiments. GCK sequence corresponds to a 
positive control for Ku recruitment. * and **: P-values < 0,05% compared to the No siRNA condition.Available online http://breast-cancer-research.com/content/11/6/R83
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to the ERBB2 promoter. Interestingly, the inhibition of AP-2α
and AP-2γ expression by siRNA strongly reduced Ku70
recruitment to the ERBB2 promoter. Ku70 siRNA reduced by
half the recruitment of AP-2 factors to the -500 bp region of
the ERBB2 promoter containing a high affinity AP2BS. More
importantly, Ku70 siRNA downregulated PolII recruitment to
the ERBB2 promoter. These results show that the Ku proteins
are involved in ERBB2 gene expression regulation by AP-2 in
breast cancer cells.
In addition to their role in the repair of DNA double strand
breaks, Ku proteins have been shown to control other impor-
tant cellular processes such as transcription and apoptosis.
Ku proteins modulate transcription by several mechanisms
and these properties seem to be gene and cell specific. For
example, DNA binding of the Ku70/Ku80 heterodimer is
responsible for the downregulation of glycoprotein glycoph-
orin B in non erythroid cells [38]. In contrast, Ku binding to
apolipoprotein C-IV promoter stimulates the expression of the
gene [39]. Another study showed that interleukins -13/-4
induced expression of the lipooxygenase-1 gene is mediated
by the binding of Ku dimmers to the promoter [40]. C-jun
expression is also stimulated by Ku80 and possibly by Ku70
binding to gene promoter [41]. Ku proteins can also influence
transcription by interaction with transcription factors or cofac-
tors. So, Ku binding inhibits ESE1, an Ets family transcription
factor, from binding to DNA and thus its transcriptional activity
[42]. Ku proteins might also be involved in elongation [37] and
transcription reinitialization [43].
Ku proteins were also shown to modulate gene expression by
binding to PARP-1 and to YY1, which were shown to interact
with and influence AP-2 transcription factor activity. Indeed,
PARP-1 is necessary to preserve the transcriptional activity of
overexpressed AP-2 transcription factors [18]. The Ku - PARP
interaction has opposing effects on transcription. Ku proteins
inhibit the transcriptional activity of β-catenin-TCF4 complex
by interfering with PARP-1 binding [44]. In contrast, the Ku70/
Ku80 dimmer - PARP-1 complex stimulates the expression of
the S10019 gene [45]. Ku - YY1 interaction inhibits α myosin
heavy-chain gene expression in the heart [46], contrary to the
consequence of YY1 interaction with AP-2 on ERBB2 gene
expression [20].
Conclusions
In summary, the present study contributes to a better under-
standing of the regulation of ERBB2 gene expression in breast
cancer cells, by demonstrating the implication of Ku proteins
together with AP-2 transcription factors in the expression of
the oncogene. Our results implicate Ku proteins in breast can-
cer by contributing to ERBB2 gene overexpression and thus
the accumulation of excessive amounts of the receptor. Under-
standing the mechanisms of ERBB2 gene deregulation might
help in the development of drugs that target further key ele-
ments responsible for this important deregulation. Among
these, inhibiting Ku activity might be evaluated as an adjuvant
for ERBB2 targeted therapy in breast cancer. However, more
work is needed in models resembling the in vivo situation to
confirm the implication of Ku proteins in the accumulation of
excessive amounts of ERBB2 protein in cancerous cells.
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